An interventional study of Sleep Restriction Therapy in Autism Spectrum Disorder (ASD) and Autism, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Autistic Disorder by Stanford University — 16 open to participants now, 16 under way, none of them phase 3. Autistic Disorder · Stanford University.
Among the 33 studies in Autistic Disorder by Stanford University, this one is the 28th largest by planned enrollment, is one of 3 that started in 2025, is one of 21 with no phase, reaches primary completion later than 2 of the 15 other live ones, and was the 31st registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →16 of the 33 studies in Autistic Disorder by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 2–5 · Healthy volunteers
Stanford University · Sites in United States
Ages 6–11 · Healthy volunteers
Stanford University · Sites in United States
Ages 4–17 · Healthy volunteers
Stanford University · Sites in United States
Ages 3–35
Stanford University · Sites in United States
Ages 11–14
By country, each count listing its studies:
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 1
First in 2008; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Median enrollment 48 across the 33 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
4 of the studies in Autistic Disorder by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06627205Stanford UniversitySleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism | 2026-12 |
| NCT05987774Stanford UniversityImproving Social Communication in Individuals With ASD Using AI | 2027-06-30 |
| NCT06472115Stanford UniversityParent-Mediated Intervention Targeting Insistence on Sameness for Autistic Children | 2027-10-01 |
| NCT03583684Stanford UniversityNeuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Autistic Disorder by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this open label trial is to examine the acceptability, tolerability, and feasibility and preliminary effectiveness of sleep restriction therapy for sleep problems in children with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of parent-training in delivering the intervention.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
This study's planned enrollment of 25 is below the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants attend telehealth sessions once per week for three weeks and implement sleep restriction therapy in between sessions and for 4 weeks during a follow-up period.
Behavioral: Sleep Restriction Therapy
Therapist led sleep restriction therapy sessions.
Acceptability of Sleep Restriction Therapy
Acceptability will be assessed using a series of questions rated by participants on a 5-point Likert scale (1-5) with 1 being the least acceptable and 5 being the most acceptable.
Time frame: At end of treatment (approximately week 10)
Tolerability of Sleep Restriction Therapy
Tolerability will be assessed using a series of questions rated by participants on a 5-point Likert scale (1-5) with 1 being the least tolerable and 5 being the most tolerable.
Time frame: At end of treatment (approximately week 10)
Feasibility of Sleep Restriction Therapy
Feasibility will be assessed using a series of questions rated by participants on a 5-point Likert scale (1-5) with 1 being the least feasible and 5 being the most feasible.
Time frame: At end of treatment (approximately week 10)
Change from baseline on the Sleep Disturbance Scale for Children
The Sleep Disturbance Scale for Children (SDSC) evaluates various sleep disorders including difficulties in falling asleep and staying asleep, sleep-disordered breathing, arousal disorders, sleep-wake transition disorders, excessive sleepiness, and excessive sweating during sleep. Scores range from 26 to 130. Higher scores on the SDSC are indicative of greater sleep disturbance. This outcome measure will determine the effectiveness of sleep restriction therapy in improving sleep disturbances in children with autism spectrum disorder.
Time frame: Screening, Baseline, End of Week 2 Treatment, End of Treatment (approximately week 10)
Change in sleep onset latency (Sleep-Wake Diary)
This study utilizes a brief sleep-wake diary to collect parent-reported sleep variables (e.g., what time did your child try to sleep last night). Average sleep onset latency will be calculated from the diary for the purposes of this study.
Time frame: Baseline, Week 1, Week 2, during 4-week follow-up period, End of Treatment (approximately week 10)
Change in sleep efficiency (Sleep-Wake Diary)
This study utilizes a brief sleep-wake diary to collect parent-reported sleep variables (e.g., what time did your child try to sleep last night). Average sleep efficiency will be calculated from the diary for the purposes of this study.
Time frame: Baseline, Week 1, Week 2, during 4-week follow-up period, End of Treatment (approximately week 10)
Change in wake after sleep onset duration (Sleep-Wake Diary)
This study utilizes a brief sleep-wake diary to collect parent-reported sleep variables (e.g., what time did your child try to sleep last night). Average wake after sleep onset will be calculated from the diary for the purposes of this study.
Time frame: Baseline, Week 1, Week 2, during 4-week follow-up period, End of Treatment (approximately week 10)
Change in sleep onset latency (Actigraphy)
Children wear an actigraphy monitor for the purposes of collecting objective information about sleep onset latency (time taken to fall asleep).
Time frame: Baseline, Week 1, Week 2
Change in sleep efficiency (Actigraphy)
Children wear an actigraphy monitor for the purposes of collecting objective information about sleep efficiency (percentage of time in bed that the child is actually asleep).
Time frame: Baseline, Week 1, Week 2
Change in Wake After Sleep Onset (Actigraphy)
Children wear an actigraphy monitor for the purposes of collecting objective information about wake after sleep onset duration (the amount of time spent awake after falling asleep)
Time frame: Baseline, Week 1, Week 2
Plan to share: No — No current plan to share data.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 22 months is below that.
Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.